Provided by Tiger Trade Technology Pte. Ltd.

Neumora Therapeutics, Inc.

1.39
-0.0900-6.08%
Pre-market: 1.500.1113+8.01%04:50 EDT
Volume:696.29K
Turnover:999.83K
Market Cap:261.32M
PE:-1.14
High:1.51
Open:1.50
Low:1.38
Close:1.48
52wk High:3.65
52wk Low:0.8302
Shares:188.00M
Float Shares:116.00M
Volume Ratio:1.09
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2237
EPS(LYR):-1.4501
ROE:-187.11%
ROA:-73.85%
PB:5.87
PE(LYR):-0.96

Loading ...

ANI Pharma Appoints Henry Gosebruch to Board of Directors

Reuters
·
Aug 24

Top Neumora Executive Makes Notable Move With Insider Stock Sale

TIPRANKS
·
Aug 22

Neumora Chief Operating and Development Officer Aurora Daljit Singh Disposes of USD 135,222.93 in Common Shares

Reuters
·
Aug 22

Neumora Therapeutics COO and Chief Development Officer Aurora Daljit Singh Disposes of 242,773 Common Shares Worth USD 377,639.16

Reuters
·
Aug 20

Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital

TIPRANKS
·
Aug 18

Neumora Therapeutics reports Q2 EPS (23c), consensus (24c)

TIPRANKS
·
Aug 16

Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed

TIPRANKS
·
Aug 16

Neumora Therapeutics, Inc. (NMRA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 15

Neumora Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Neumora Therapeutics Posts Corporate Presentation on Neuroscience Drug Development Strategy

Reuters
·
Aug 14

Neumora Therapeutics Promotes Pinto to CEO

Dow Jones
·
Aug 14

Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate

Benzinga Earnings
·
Aug 14

Neumora Therapeutics - Appoints Joshua Pinto as President and CEO and Board Member

THOMSON REUTERS
·
Aug 14

Neumora Therapeutics - Q2 2026 Net Loss $43.10 Mln vs $52.70 Mln in Q2 2025

THOMSON REUTERS
·
Aug 14

Neumora Therapeutics - Paul L. Berns to Serve as Executive Chair

THOMSON REUTERS
·
Aug 14

Press Release: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

Neumora Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Neumora Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Jul 28

Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis

TIPRANKS
·
Jul 27